Lakefront Biotherapeutics (GLPGF) Free Cash Flow (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Free Cash Flow for 13 consecutive years, with -$96.7 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 174.42% year-over-year to -$96.7 million in Q1 2026; TTM through Mar 2026 was -$142.1 million, a 67.8% decrease from a year earlier, with the FY2025 full-year figure at -$275.4 million, up 16.11% from the prior year.
• Free Cash Flow was -$96.7 million for Q1 2026 at Lakefront Biotherapeutics, down from -$53.4 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $4.7 million in Q2 2025 and troughed at -$482.7 million in Q4 2022.
• A 5-year average of -$108.6 million and a median of -$57.6 million in 2024 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow jumped 86.16% in 2024 and tumbled 174.42% in 2026, its largest moves.
• Over 5 years, Free Cash Flow stood at -$482.7 million in 2022, then increased by 13.69% to -$416.7 million in 2023, then jumped by 86.16% to -$57.6 million in 2024, then gained by 7.41% to -$53.4 million in 2025, then sank by 81.22% to -$96.7 million in 2026.
• The last three Free Cash Flow figures came in at -$96.7 million (Q1 2026), -$53.4 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.